Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia,

Next Previous
Search
Trial Profile

A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia,

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eprotirome (Primary)
  • Indications Hypercholesterolaemia
  • Focus Biomarker; Therapeutic Use
  • Sponsors Karo Bio

    • Most Recent Events

    • 24 Sep 2009 Results will be presented at the 80th Annual Meeting of the American Thyroid Association (ATA), held September 23-27, 2009, Florida, US, according to a Karo Bio media release.
    • 30 Oct 2008 Top line data has been reported by Karo Bio in a media release.
    • 23 Oct 2008 Status changed from recruiting to completed, as reported in a Karo Bio media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top